Chinese biopharmaceutical company Sinovant Sciences revealed on Thursday that its Clinical Trial Application (CTA) for lefamulin has been approved by the Center for Drug Evaluation at the National Medical Products Administration (NMPA) in China.
Following the NMPA's approval, the company will initiate registrational clinical trials for patients with community-acquired bacterial pneumonia (CABP) in the second half of 2019.
According to Sinovant Sciences, lefamulin is a novel antibiotic of the pleuromutilin class being developed as a potential treatment for CABP. Lefamulin is a semi-synthetic pleuromutilin antibiotic which works by selectively inhibiting translation of bacterial protein synthesis. Widespread use of antibiotics has created high resistance to common first line antibiotics among causative pathogens and industry estimates suggest there are as many as 18m new cases of CABP each year in China, one of the leading causes of mortality in the country.
In the company's pre-clinical studies, lefamulin has demonstrated a targeted spectrum of activity against the pathogens that commonly cause CABP, including multi-drug resistant strains. In two global Phase 3 studies of lefamulin in patients with moderate and severe CABP, lefamulin was demonstrated to be non-inferior to moxifloxacin and met both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) primary and secondary efficacy endpoints for the treatment of CABP.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML